Evidence mapPaperPMID 41918359Full record

ArticleCancer discovery2026

Fiber: A New Myeloma Prevention Approach with Abundant Positive Effects.

Heather Fairfield, Michaela R Reagan

Abstract read
In one paragraph

Article in Cancer discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Heather FairfieldCenter for Molecular Medicine, MaineHealth Institute for Research, Scarborough, Maine.ORCID 0000-0002-8852-2254
Michaela R ReaganCenter for Molecular Medicine, MaineHealth Institute for Research, Scarborough, Maine.ORCID 0000-0003-2884-6481

Funding

Translational Research Technologies CoreU54GM115516 · MAINEHEALTH · 2025 to 2025
$4.0M
The role of night shift work in metabolic disorders during and after pregnancyP20GM121301 · MAINEHEALTH · 2025 to 2025
$2.6M
Defining the Roles of Bone Marrow Adipocytes and FABP4/5 Signaling in Multiple Myeloma Drug ResistanceR37CA245330 · MAINEHEALTH · 2025 to 2025
$787k
Research Specialist Support for Defining the Roles of Bone Marrow Adipocytes and FABP4/5 Signaling in Multiple MyelomaR50CA265331 · MAINEHEALTH · 2025 to 2025
$100k
NCI NIH HHS R37 CA245330NCI NIH HHS R50 CA265331NIGMS NIH HHS P20 GM121301NIGMS NIH HHS U54 GM115516
6 · The paper itself

Abstract

In a recent study by Shah, Cogrossi, and colleagues, patients with overweight/obesity and pre-myeloma diseases (monoclonal gammopathy of undetermined significance or smoldering myeloma) were mailed 12 weeks of high-fiber meals, provided with nutritional counseling, and required to track their food intake and weight. The intervention was well tolerated and improved quality of life, metabolic health, gut microbiome composition, and immune system function while supporting stable or improved multiple myeloma disease trajectories. See related article by Shah et al., p. 697.

Indexed as

Dietary FiberMultiple MyelomaHumansObesityQuality of LifeDietary Fiber

Identifiers

PMID41918359
PMCPMC13182222

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.